X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.pmlive.com/pharma_news/nice_recommends_chiesis_elfabrio_for_adults_with_fabry_disease_1497865
https://www.ema.europa.eu/en/documents/overview/elfabrio-epar-medicine-overview_en.pdf
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761161
https://www.pharmatimes.com/news/protalix_and_chiesi_gain_positive_opinion_for_pegunigalsidase_alfa_1488829
https://www.europeanpharmaceuticalreview.com/news/179980/chmp-recommends-first-pegylated-enzyme-for-fabry-disease/
https://www.biospace.com/article/releases/chiesi-global-rare-diseases-and-protalix-biotherapeutics-receive-positive-chmp-opinion-for-pegunigalsidase-alfa-for-treatment-of-fabry-disease/
https://www.prnewswire.com/news-releases/protalix-biotherapeutics-and-chiesi-global-rare-diseases-announce-us-food-and-drug-administration-acceptance-of-a-resubmitted-biologics-license-application-for-pegunigalsidase-alfa-for-the-proposed-treatment-of-fabry-disease-301694436.html
https://www.thepharmaletter.com/article/chiesi-and-protalix-announce-phase-iii-data-from-bright-study-in-fabry-disease
https://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-participate-in-the-18th-annual-worldsymposium-2022-301474737.html
https://www.fiercebiotech.com/biotech/protalix-biotherapeutics-fabry-disease-drug-complete-response-letter-fda-update
https://www.globenewswire.com/news-release/2020/12/23/2150308/0/en/Chiesi-Global-Rare-Diseases-Announces-First-Patient-Treated-in-Expanded-Access-Program-for-Pegunigalsidase-Alfa-for-Proposed-Treatment-of-Fabry-Disease.html
https://www.globenewswire.com/news-release/2020/12/23/2150308/0/en/Chiesi-Global-Rare-Diseases-Announces-First-Patient-Treated-in-Expanded-Access-Program-for-Pegunigalsidase-Alfa-for-Proposed-Treatment-of-Fabry-Disease.html
https://www.prnewswire.com/news-releases/protalix-biotherapeutics-and-chiesi-global-rare-diseases-announce-submission-of-biologics-license-application-to-us-food-and-drug-administration-for-pegunigalsidase-alfa-for-the-treatment-of-fabry-disease-301066794.html
Market Place
Share 
